KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBIT Margin (2016 - 2025)

Travere Therapeutics' EBIT Margin history spans 13 years, with the latest figure at 25.0% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 5621.0% year-over-year to 25.0%; the TTM value through Dec 2025 reached 17.17%, up 12171.0%, while the annual FY2025 figure was 12.8%, 12608.0% up from the prior year.
  • EBIT Margin reached 25.0% in Q4 2025 per TVTX's latest filing, down from 62.33% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 62.33% in Q3 2025 to a low of 336.53% in Q1 2024.
  • Average EBIT Margin over 5 years is 165.73%, with a median of 125.11% recorded in 2024.
  • Peak YoY movement for EBIT Margin: crashed -23657bps in 2022, then soared 28432bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 57.66% in 2021, then plummeted by -413bps to 295.52% in 2022, then increased by 29bps to 209.13% in 2023, then soared by 61bps to 81.21% in 2024, then soared by 69bps to 25.0% in 2025.
  • Per Business Quant, the three most recent readings for TVTX's EBIT Margin are 25.0% (Q4 2025), 62.33% (Q3 2025), and 11.05% (Q2 2025).